Long-term experience with the 1stQ AddOn trifocal supplementary intraocular lens

Session Details

Session Title: Advanced Optic IOLs

Session Date/Time: Tuesday 17/09/2019 | 08:30-10:30

Paper Time: 08:54

Venue: Free Paper Forum: Podium 1

First Author: : C.Palomino Bautista SPAIN

Co Author(s): :                                 

Abstract Details

Purpose:

To evaluate the refractive and functional outcome of the trifocal 1stQ AddOn supplementary intraocular lens (IOL) designed for implantation into the ciliary sulcus.

Setting:

Department of Ophthalmology, Quirón University Hospital, Madrid, Spain

Methods:

Twenty-two eyes of sixteen pseudophakic patients (10 patients were implanted mono- and 6 patients binocularly) with uncomplicated previous implantation of monofocal capsular bag IOLs, who wish for spectacle independence were included in our investigation. After 1 year of follow-up, distance, intermediate and near visual acuities, as well as defocus tolerance were measured, and defocus curves were plotted. The safety of the IOL in our focus was tested by intraocular pressure (IOP) registration, endothelial cell density measurements and biomicroscopic evaluation.

Results:

Visual acuities for distance, intermediate and near vision, and defocus curves clearly confirmed trifocal optical performance (UCDVA=0.02 ± 0.08; UCIVA=0.22 ± 0.12; UCNVA=0.14 ± 0.06 logMAR; expressed as mean ± SD). All patients achieved spectacle independence at all distances. Postoperative refractions (SEQ) were close to plano (-0.015 ± 0.09), and the IOL was set stable in the sulcus. Depth of focus evaluations showed an identical defocus tolerance (DOF=0.486 D) with a capsular bag trifocal IOL. Examinations proved safety even in the long-term, as no unfavourable change in either in endothelial cell count, IOP or angular structure could be observed.

Conclusions:

According to our results, the Add-On Trifocal supplementary IOL by 1stQ Medicontur seems to be a safe, efficient and stable solution even in the long-term, for achieving spectacle independence in pseudophakic patients with monofocal primary IOLs.

Financial Disclosure:

None